Lessin M S, Thompson I M, Deprez M F, Cullen M L, Whittlesey G C, Klein M D
Department of Surgery, Wayne State University, Detroit, MI, USA.
J Am Coll Surg. 1995 Jul;181(1):65-71.
Congenital diaphragmatic hernia (CDH) continues to have a high mortality rate (24 to 57 percent) despite changing management schemes, which include extracorporeal membrane oxygenation (ECMO) for treatment of associated persistent pulmonary hypertension of the newborn.
The medical records of 123 acutely symptomatic newborns with CDH treated from 1972 to 1994 were retrospectively reviewed. Patients were divided into three groups to compare historical treatment modalities: group 1, no ECMO available; group 2, postoperative ECMO if necessary; and group 3, delayed repair with preoperative ECMO if necessary. The blood gas values, alveolar-arterial oxygen gradient (A-aDO2), mean airway pressure (MAP), and oxygenation (OI) and ventilation indices (VI) prior to treatment were compared between survivors and nonsurvivors. Chi-square and Student's t tests were used to determine statistical significance.
The overall survival rate was 41 percent: 27 percent in group 1, 45 percent in group 2, and 39 percent in groups 3. If those who were not candidates for ECMO were excluded from analysis, the survival rate improved to 35 percent in group 1, 51 percent in group 2, and 50 percent in group 3. No published prognostic scoring system, such as arterial blood gas values, A-aDO2 gradient, MAP, OI, or VI consistently distinguished survivors from nonsurvivors. Extracorporeal membrane oxygenation decreased the mortality rate of patients having large defects.
Prognostic scoring systems do not predict which patients with CDH should be treated. Extracorporeal membrane oxygenation has improved survival in newborns with CDH who present in early respiratory distress. There is no advantage or disadvantage to using ECMO prior to repair of CDH.
尽管治疗方案不断变化,包括采用体外膜肺氧合(ECMO)治疗新生儿相关持续性肺动脉高压,但先天性膈疝(CDH)的死亡率仍然很高(24%至57%)。
回顾性分析了1972年至1994年期间接受治疗的123例急性症状性CDH新生儿的病历。将患者分为三组以比较不同的历史治疗方式:第1组,无ECMO可用;第2组,必要时术后使用ECMO;第3组,必要时术前使用ECMO并延迟修复。比较了幸存者和非幸存者治疗前的血气值、肺泡-动脉氧梯度(A-aDO2)、平均气道压(MAP)以及氧合(OI)和通气指数(VI)。采用卡方检验和学生t检验确定统计学意义。
总体生存率为41%:第1组为27%,第2组为45%,第3组为39%。如果将那些不适合使用ECMO的患者排除在分析之外,第1组的生存率提高到35%,第2组为51%,第3组为50%。没有一种已发表的预后评分系统,如动脉血气值、A-aDO2梯度、MAP、OI或VI能够持续区分幸存者和非幸存者。体外膜肺氧合降低了大缺损患者的死亡率。
预后评分系统无法预测哪些CDH患者应接受治疗。体外膜肺氧合提高了早期出现呼吸窘迫的CDH新生儿的生存率。在CDH修复术前使用ECMO没有优势或劣势。